BioArctic AB (CHIX:BIOABs)

Q4 2025 BioArctic AB Earnings Call Transcript

Feb 18, 2026 / 08:30 AM GMT

Release Date Price: kr321.8

Transcript

Key Points

Positve

BioArctic AB (BRCTF) reported record financial results for 2025, marking a transformative year with significant growth.
The company has expanded its portfolio with new projects targeting Parkinson's-related diseases and Huntington's disease.
BioArctic AB (BRCTF) has established successful global partnerships with major pharmaceutical companies like Bristol Myers Squibb and Novartis.
The company's brain transporter technology is evolving, offering innovative ways to deliver antibodies and other modalities into the brain.
Lekembi, a treatment for Alzheimer's disease, has achieved global sales exceeding $500 million and is approved in 53 countries.

Negative

The adoption of Lekembi in Europe is slower compared to other regions, with ongoing reimbursement discussions in several countries.
Operating expenses are expected to increase significantly in 2026 due to the progression of the project portfolio.
There is uncertainty regarding the cost-effectiveness of Lekembi in the Nordics, particularly following a negative recommendation in Denmark.
The company's financial results were impacted by currency fluctuations, affecting royalty growth.
Despite strong financial performance, there is no clear forecast for future dividend payouts, creating uncertainty for investors.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BIOAb.ST - BioArctic AB
Q4 2025 BioArctic AB Earnings Call
Feb 18, 2026 / 08:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Biotics presentation for the 4th quarter and for the full year of 2025.

It has been a fantastic year for biotics.

In 2025, we entered into a new era that we call the growth era.

And we can conclude that we have a transformative year behind us with record financial results.

We are making our science accessible to more and more patients than ever before, and I think it's great and reassuring to see that more and more patients are getting access to Lekembi.

We are accelerating our innovations. Our portfolio is progressing really well and has been further expanded, and our brain transporter technology is further evolving with new innovations.

We have increased focus

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.